M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 53 of 54
Rituximab and ABVD for Hodgkin's Patients
NCT00504504
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
NCT00038610
Therapy of Early Chronic Phase CML With Gleevec
NCT00048672
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
NCT00048100
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
NCT00037882
Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy
NCT00548756
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
NCT00037609
Chemotherapy-Related Toxicities In Ovarian Cancer Patients
NCT00508378
Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
NCT00427336
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
NCT00038181
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
NCT00038246
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
NCT00038792
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
NCT00041782
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00006471
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
NCT00506922
Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer
NCT00082732
DNA Array Analysis of Patients With Cervical Cancer
NCT00512551
Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
NCT04465162
Thalidomide-Dexamethasone for Multiple Myeloma
NCT00038090
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
NCT00038207
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
NCT00038168
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
NCT00006081
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma
NCT00386906
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
NCT00303290
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00004263
Docetaxel in Treating Patients With Metastatic Breast Cancer
NCT00008411
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
NCT01939730
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
NCT00512096
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
NCT00038701
rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin
NCT00038012
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
NCT00667329
Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
NCT00507182
Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer
NCT00473798
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
NCT00003645
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
NCT00038584
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00005092
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367
Transition From Research to Disclosure in Human Genetics
NCT00505466
Thalidomide for Multiple Myeloma
NCT00038233
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
NCT00038051
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
NCT00003677
Clofarabine in Chronic Lymphocytic Leukemia
NCT00028418
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
NCT00003693
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
NCT00004142
Irofulven in Treating Patients With Metastatic Colorectal Cancer
NCT00003441
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
NCT00004154
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00006079
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00003311
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
NCT00084903
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
NCT00577993
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.